亚美尼亚 - 英文 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi pasteur - diphtheria toxoid, tetanus toxoid, pertussis toxoid/filamentous haemagglutinin, poliovirus types 1/2/3, hepatitis b surface antigen, haemophilus infuenzae type b polysaccharide, haemophilus infuenzae type b polysaccharide conjugated to tetanus protein - suspension for injection - 20iu/0,5ml+ 40iu/0,5ml+ 25/25mcg/0,5ml+ 40/8/32 du/0,5ml+ 10mcg/0,5ml+ 12mcg/0,5ml+ 22-36mcg/0,5ml

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

statens serum institute - diphtheria toxoid, tetanus toxoid - suspension for injection - per cent - tetanus vaccines

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

statens serum institute - diphtheria toxoid, purified, tetanus toxoid, purified, pertussis toxoid, purified, aluminium hydroxide, hydrate corr. to aluminium - suspension for injection - 0.5 milligram - benzothiazepine derivatives

新加坡 - 英文 - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid; filamentous haemagglutinin; hepatitis b surface antigen (purified); hib purified capsular polysaccharide bound to tetanus toxoid; pertactin (69 kda omp); pertussis toxoid; poliovirus type 1 (inactivated); poliovirus type 2 (inactivated); poliovirus type 3 (inactivated) - injection - min 30 iu/0.5 ml - diphtheria toxoid min 30 iu/0.5 ml; filamentous haemagglutinin 25 mcg/0.5 ml; hepatitis b surface antigen (purified) 10 mcg/0.5 ml; hib purified capsular polysaccharide bound to tetanus toxoid 10 mcg/0.5 ml; pertactin (69 kda omp) 8 mcg/0.5 ml; pertussis toxoid 25 mcg/0.5 ml; poliovirus type 1 (inactivated) 40 du/0.5 ml; poliovirus type 2 (inactivated) 8 du/0.5 ml; poliovirus type 3 (inactivated) 32 du/0.5 ml

新加坡 - 英文 - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid (d); filamentous haemagglutinin (fha); hib purified capsular polysaccharide; pertactin (prn or 69kda outer membrane protein); pertussis toxoid (pt); polio virus type 1 (inactivated); polio virus type 2 (inactivated); polio virus type 3 (inactivated); tetanus toxoid (t) - injection - min 30iu/0.5ml - diphtheria toxoid (d) min 30iu/0.5ml; filamentous haemagglutinin (fha) 25mcg/0.5ml; hib purified capsular polysaccharide 10 mcg/0.5 ml; pertactin (prn or 69kda outer membrane protein) 8mcg/0.5ml; pertussis toxoid (pt) 25mcg/0.5ml; polio virus type 1 (inactivated) 40du/0.5ml; polio virus type 2 (inactivated) 8du/0.5ml; polio virus type 3 (inactivated) 32du/0.5ml; tetanus toxoid (t) min 40iu/0.5ml

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diphtheria toxoid, quantity: 2 iu; pertussis filamentous haemagglutinin, quantity: 5 microgram; pertussis toxoid, quantity: 2.5 microgram; pertussis fimbriae 2 + 3, quantity: 5 microgram; pertactin, quantity: 3 microgram; tetanus toxoid, quantity: 20 iu - injection, suspension - excipient ingredients: glutaral; formaldehyde; phenoxyethanol; water for injections; aluminium phosphate - adacel is indicated for active immunisation against tetanus, diphtheria and pertussis in persons aged 10 years and over as a booster following primary immunisation. adacel may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus.

亚美尼亚 - 英文 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin - suspenion for injection - not less than 30iu/dose+ not less than 40iu/dose+ 25mcg/dose+ 25mcg/dose+ 8mcg/dose

亚美尼亚 - 英文 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin, hepatitis b surface antigen, inactivated poliovirus type 1, inactivated poliovirus type 2, inactivated poliovirus type 3, haemophilus influenzae type b polysaccharide (conjugated to tetanus toxoid) - powder and suspension for suspension for injection - not less than 30iu/dose+ not less than 40iu/dose+ 25mcg/dose+ 25mcg/dose+ 8mcg/dose+ 10mcg/dose+ 40d-antigen unit/dose+ 8d-antig

亚美尼亚 - 英文 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin, hepatitis b surface antigen, type 1 (mahoney) 40 d antigen, type 2 (mef-1) 8d antigen, type 3 (saukett) 32d antigen, haemophilus influenzae type b polysaccharide (conjugated to tetanus toxoid) - powder and suspension for suspension for injection - not less than 30iu/0,5ml+ not less than 40iu/0,5ml+ 25mcg/0,5ml+ 25mcg/0,5ml+ 8mcg/0,5ml+ 10mcg /0,5ml+ units/0,5ml+ units/0,5ml+ units/0,5ml+ 10mcg /0,5ml

加拿大 - 英文 - Health Canada

sanofi pasteur limited - tetanus toxoid; diphtheria toxoid; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney - suspension - 5lf; 2lf; 32unit; 8unit; 40unit - tetanus toxoid 5lf; diphtheria toxoid 2lf; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32unit; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8unit; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40unit - toxoids